Skip to main content

Table 1 Summary of clinical data

From: C-reactive protein as a potential biomarker for disease progression in dengue: a multi-country observational study

Characteristic

n

OFI (N = 394)

n

All dengue patients (N = 1117)

n

Uncomplicated dengue (N = 836)

n

Intermediate dengue (N = 243)

n

Severe dengue (N = 38)

Country

394

 

1117

 

836

 

243

 

38

 

 Cambodia

 

0 (0.0)

 

99 (8.9)

 

69 (8.3)

 

20 (8.2)

 

10 (26.3)

 El Salvador

 

0 (0.0)

 

41 (3.7)

 

23 (2.8)

 

12 (4.9)

 

6 (15.8)

 Malaysia

 

0 (0.0)

 

117 (10.5)

 

88 (10.5)

 

26 (10.7)

 

3 (7.9)

 Vietnam

 

394 (100.0)

 

860 (77.0)

 

656 (78.5)

 

185 (76.1)

 

19 (50.0)

Age (year)

394

15 (8, 27)

1117

15 (10, 25)

836

14 (10, 25)

243

17 (11, 26)

38

10 (8, 14)

Gender male, n (%)

394

241 (61.2)

1117

637 (57.0)

836

467 (55.9)

243

147 (60.5)

38

23 (60.5)

DOI at enrollment, n (%)

394

 

1117

 

836

 

243

 

38

 

 1

 

99 (25.1)

 

225 (20.1)

 

176 (21.1)

 

42 (17.3)

 

7 (18.4)

 2

 

162 (41.1)

 

555 (49.7)

 

425 (50.8)

 

117 (48.1)

 

13 (34.2)

 3

 

133 (33.8)

 

337 (30.2)

 

235 (28.1)

 

84 (34.6)

 

18 (47.4)

Serotype, n (%)

–

 

1049

 

782

 

231

 

36

 

 DENV-1

 

–

 

435 (41.5)

 

314 (40.2)

 

101 (43.7)

 

20 (55.6)

 DENV-2

 

–

 

186 (17.7)

 

139 (17.8)

 

42 (18.2)

 

5 (13.9)

 DENV-3

 

–

 

105 (10.0)

 

76 (9.7)

 

26 (11.3)

 

3 (8.3)

 DENV-4

 

–

 

323 (30.8)

 

253 (32.4)

 

62 (26.8)

 

8 (22.2)

Serology, n (%)

–

 

1117

 

836

 

243

 

38

 

 Probable primary

 

–

 

215 (19.2)

 

174 (20.8)

 

39 (16.0)

 

2 (5.3)

 Probable secondary

 

–

 

763 (68.3)

 

545 (65.2)

 

185 (76.1)

 

33 (86.8)

 Inconclusive

 

–

 

139 (12.4)

 

117 (14.0)

 

19 (7.8)

 

3 (7.9)

Used antibiotics1, n (%)

392

140 (35.7)

1115

74 (6.6)

834

46 (5.5)

243

20 (8.2)

38

8 (21.1)

DOI of starting antibiotic

139

4.0 (3.0, 5.0)

74

4.0 (3.0, 5.8)

46

4.0 (3.0, 5.0)

20

4.0 (3.0, 6.0)

8

6.5 (4.0, 8.0)

Length of fever (day)2

344

5.0 (5.0, 6.0)

914

6.0 (5.0, 7.0)

708

6.0 (5.0, 7.0)

184

7.0 (6.0, 7.0)

22

7.5 (6.0, 8.0)

Used any blood product3, n (%)

392

0 (0.0)

1117

3 (0.3)

836

0 (0.0)

243

2 (0.8)

38

1 (2.6)

Hospitalization, n (%)

394

76 (19.3)

1117

421 (37.7)

836

260 (31.1)

243

123 (50.6)

38

38 (100.0)

DOI when hospitalization

76

4.0 (3.0, 5.0)

421

5.0 (4.0, 5.0)

260

4.0 (4.0, 5.0)

123

5.0 (4.0, 5.0)

38

4.5 (4.0, 5.0)

Length of hospital stay (day)

76

4.0 (4.0, 6.0)

420

4.0 (3.0, 5.0)

260

3.0 (2.0, 4.0)

123

4.0 (3.0, 5.0)

37

5.0 (4.0, 6.0)

Clinical diagnosis of bacterial infection, n (%)

394

131 (33.2)

1117

54 (4.8)

836

38 (4.5)

243

12 (4.9)

38

4 (10.5)

 Used antibiotics4, n (%)

131

113 (86.3)

54

41 (75.9)

38

29 (76.3)

12

9 (75.0)

4

3 (75.0)

  1. Summary statistic is median (interquartile range) for numeric variables and absolute count (percentage) for categorical variables
  2. DOI day of illness, OFI other febrile illnesses
  3. 1There were 4 missing cases about the information of using antibiotic or not (2 in the OFI group and 2 in the uncomplicated dengue group)
  4. 2There were 253 cases with fever at the end of study follow-up; therefore, the time of defervescence was unknown
  5. 3There were 2 cases received platelet transfusion in the intermediate dengue group, and 1 case received whole blood transfusion in the severe dengue group
  6. 4Summary data of using antibiotics in each probable bacterial group
Back to article page

BMC Medicine

ISSN: 1741-7015

Contact us